{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["HC-7366","belzutifan"],["HC-7366"]],"indication":"locally advanced or metastatic renal cell carcinoma","name":"NCT06234605","nct_id":"NCT06234605","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06234605. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive HC-7366 monotherapy \\[dose to be determined\\] daily","label":"Monotherapy","type":"EXPERIMENTAL"},{"description":"Participants will receive HC-7366 monotherapy \\[dose to be determined\\] in combination with belzutifan \\[120 mg\\] daily","label":"Combination","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2027-11","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":80,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"HC-7366","otherNames":[],"type":"DRUG"},{"name":"Belzutifan","otherNames":["WELIREG™","MK-6482"],"type":"DRUG"}],"last_update":"2026-10-02","lead_sponsor":"HiberCell, Inc.","official_title":"A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Determination of MTD and RP2D (combination cohorts only)","timeFrame":"30 months"}],"references":[],"start_date":{"date":"2024-04-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT06234605"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06234605"}